For the quarter ending 2025-09-30, IPSC had -$913K decrease in cash & cash equivalents over the period. -$25,779K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -34,428 | 44,019 |
| Depreciation | 3,129 | 6,422 |
| Non-cash operating lease expense (benefit) | 517 | 968 |
| Stock based compensation | 892 | 4,648 |
| Impairment of long-lived asset | 6,763 | - |
| Accretion of investments | 507 | 1,501 |
| Change in fair value of contingent liabilities | -240 | -145 |
| Gain on reduction in lease liability due to lease termination | 1,395 | - |
| Prepaid expenses and other assets | -585 | -436 |
| Operating lease liability | -1,232 | -2,347 |
| Deferred revenue | 0 | -109,164 |
| Accounts payable | -591 | -4 |
| Accrued expenses and other liabilities | 443 | -5,837 |
| Net cash used in operating activities | -25,584 | -62,215 |
| Acquisition of property and equipment | 195 | 792 |
| Acquisition of fixed maturity securities, available for sale | 11,023 | 24,552 |
| Sale of fixed maturity securities, available for sale | 35,889 | 85,813 |
| Net cash provided by investing activities | 24,671 | 60,469 |
| Proceeds from issuance of common stock and espp | 0 | 120 |
| Net cash provided by financing activities | 0 | 120 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -913 | -1,626 |
| Cash and cash equivalents at beginning of period | 61,213 | - |
| Cash and cash equivalents at end of period | 58,674 | - |
Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC)